XYP-001
/ Joincare
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 20, 2022
Health Yuan: XYP-001 obtained the drug clinical trial approval notice [Google translation]
(Shanghai Securities News)
- "HealthYuan announced that the company has received the approval of the State Drug Administration to issue the 'Drug Clinical Trial Approval Notice' on XYP-001. XYP-001 is an improved new drug developed by the company. Intended for the treatment of idiopathic pulmonary fibrosis (IPF). This product is a new mechanism/target drug in the field of IPF indication development."
New trial • Idiopathic Pulmonary Fibrosis
1 to 1
Of
1
Go to page
1